Dasatinib and Dexamethasone Combination Therapy Targets Myeloma and the Tumor Microenvironment

被引：0
|
作者：
Ramasamy, K. A. [1 ]
Macpherson, L. [1 ]
Mufti, G. [1 ]
Schey, S. [1 ]
Calle, Y. [1 ]
机构：
[1] Kings Coll London, London, England
来源：
CLINICAL LYMPHOMA & MYELOMA | 2009年 / 9卷
关键词：
D O I：
10.1016/S1557-9190(11)70692-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S116 / S117
页数：2
相关论文
共 50 条
  • [31] Combination Therapy of Gemcitabine and Doxorubicin to Activate Tumor Immune Microenvironment in Chemotherapy
    Liu, Ren
    Li, Sheng
    Liu, Fanshi
    Liu, Ling
    Li, Baijun
    Liang, Hui
    INTERNATIONAL JOURNAL OF PHARMACOLOGY, 2023, 19 (02) : 286 - 295
  • [32] Bortezomib, liposomal doxorubicin and dexamethasone combination therapy for patients with relapsed or refractory multiple myeloma
    Falcone, A.
    Sanpaolo, G.
    Bodenizza, C.
    Carella, A. M.
    Dell'Olio, M.
    Mantuano, S.
    Melillo, L.
    Merla, E.
    Scalzulli, F.
    Cascavilla, N.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 147 - 148
  • [33] Tyrosine Kinase Inhibition in MM? Efficacy of the Combination of Dasatinib/Bortezomib/Dexamethasone
    de Queiroz Crusoe, E.
    Ocio, E. M.
    Maiso, P.
    San-Segundo, L.
    Fernandez, D.
    Garayoa, M.
    Pandiella, A.
    San Miguel, J.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S124 - S124
  • [34] Myeloid cells as orchestrators of the tumor microenvironment: novel targets for nanoparticular cancer therapy
    Tuettenberg, Andrea
    Steinbrink, Kerstin
    Schuppan, Detlef
    NANOMEDICINE, 2016, 11 (20) : 2735 - 2751
  • [35] Molecular machineries of pH dysregulation in tumor microenvironment: potential targets for cancer therapy
    Asgharzadeh, Mohammad Reza
    Barar, Jaleh
    Pourseif, Mohammad M.
    Eskandani, Morteza
    Niya, Mojtaba Jafari
    Mashayekhi, Mohammad Reza
    Omidi, Yadollah
    BIOIMPACTS, 2017, 7 (02) : 115 - 133
  • [36] Thalidomide and dexamethasone: therapy for multiple myeloma
    Kumar, Shoji
    Rajkumar, S. Vincent
    EXPERT REVIEW OF ANTICANCER THERAPY, 2005, 5 (05) : 759 - 766
  • [37] Induction therapy in a multiple myeloma mouse model using a combination of AS101 and melphalan, and the activity of AS101 in a tumor microenvironment model
    Hayun, Michal
    Saida, Hagar
    Albeck, Michael
    Peled, Alpha
    Haran-Ghera, Nechama
    Sredni, Benjamin
    EXPERIMENTAL HEMATOLOGY, 2009, 37 (05) : 593 - 603
  • [38] Direct Effect on the Stroma by the Conventional Anti-Multiple Myeloma Drug Dexamethasone Results In Resistance of Multiple Myeloma plasma Cells Against Therapy. Sensitisation to Dexamethasone by the Kinase Inhibitor Dasatinib
    Ramasamy, Karthik
    Khatun, Hazera
    Macpherson, Lee
    Mufti, Ghulam J.
    Schey, Stephen
    Calle, Yolanda
    BLOOD, 2010, 116 (21) : 803 - 803
  • [39] Molecular Imaging of Post-Src Inhibition Tumor Signatures for Guiding Dasatinib Combination Therapy
    Gao, Liquan
    Liu, Hao
    Sun, Xianlei
    Gao, Duo
    Zhang, Chenran
    Jia, Bing
    Zhu, Zhaohui
    Wang, Fan
    Liu, Zhaofei
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57 (02) : 321 - 326
  • [40] Tumor lysis syndrome following thalidomide and dexamethasone therapy for newly diagnosed multiple myeloma
    Huston, Alissa
    Brown, Jason
    Roodman, G. David
    EXPERIMENTAL HEMATOLOGY, 2006, 34 (12) : 1616 - 1616
12345